Literature DB >> 1360101

WHO clofibrate/cholesterol trial: clarifications.

J A Heady, J N Morris, M F Oliver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1360101     DOI： 10.1016/0140-6736(92)92588-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.

Authors:  S Warshafsky; D Packard; S J Marks; N Sachdeva; D M Terashita; G Kaufman; K Sang; A J Deluca; S J Peterson; W H Frishman
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

3.  Does low cholesterol cause death?

Authors:  J E Rossouw; A M Gotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

4.  Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials.

Authors:  M F Muldoon; S B Manuck; A B Mendelsohn; J R Kaplan; S H Belle
Journal:  BMJ       Date:  2001-01-06

Review 5.  Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Authors:  Jean-Pierre Després; Isabelle Lemieux; Sander J Robins
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors:  M R Law; N J Wald; S G Thompson
Journal:  BMJ       Date:  1994-02-05

7.  Cholesterol lowering and mortality: the importance of considering initial level of risk.

Authors:  G D Smith; F Song; T A Sheldon
Journal:  BMJ       Date:  1993-05-22

Review 8.  Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.

Authors:  Stefanos Bonovas; Georgios K Nikolopoulos; Pantelis G Bagos
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 9.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006

10.  All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

Authors:  Raffaele De Caterina; Tanya Salvatore; Roberto Marchioli
Journal:  Data Brief       Date:  2016-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.